Showing 1171-1180 of 5089 results for "".
Drug-Induced Dermatomyositis
https://practicaldermatology.com/topics/atopic-dermatitis/drug-induced-dermatomyositis/23357/It’s common practice to screen for underlying malignancy in dermatomyositis, but it is also important to look for drug-induced disease.Case Report: Henoch-Schönlein Purpura in an Adult; Resident Salary Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/case-report-henoch-schnlein-purpura-in-an-adult-resident-salary-report/20909/The Future of Atopic Dermatitis Therapy
https://practicaldermatology.com/topics/general-topics/the-future-of-atopic-dermatitis-therapy/21143/As new research elucidates the individual mechanisms of atopic dermatitis, the development of therapies that more directly influence the disease may change the scope of treatment.A Case of Pemphigus Foliaceus
https://practicaldermatology.com/topics/infections-infectious-disease/a-case-of-pemphigus-foliaceus/23156/A case-based discussion of an immunobullous disorder.Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyTopical CBD For Skincare: Key Considerations
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-cbd-for-skincare-key-considerations/23701/Topically applied CBD shows promise, but there is still a lot to learn.Physician Spotlight
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight/20825/Advances in the Treatment of Reticular Erythematous Mucinosis
https://practicaldermatology.com/youngmd-connect/resident-resource-center/advances-in-the-treatment-of-reticular-erythematous-mucinosis/23491/Considering nicotinamide’s anti-inflammatory properties for inflammatory dermatological conditions to avoid steroid and antibiotic overuse.Open Payments Program: Does it Enhance Open Discussion About Financial Ties Between Dermatologists and Industry?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/open-payments-program-does-it-enhance-open-discussion-about-financial-ties-between-dermatologists-and-industry/23619/The majority of physicians practicing in the United States have received some form of compensation from private industry during their careers. These payments may include consulting fees, compensation for speaking engagements, and stock options. Certain payments take indirect forms, such as physicRIP Clarisonic, Hello New Contenders
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/rip-clarisonic-hello-new-contenders/23354/CSF faculty share top picks for at-home beauty devices.